Exact Therapeutics As · OSL:EXTX
Exact Therapeutics As — Investor Presentation (December 2024)
26 slides from Exact Therapeutics As's investor presentation, Dec 4, 2024
Slide 1: EXACT Therapeutics Market update
EXACT Therapeutics Defeating biological barriers - in tumours Market update December 4, 2024
Slide 2: Important notice and disclaimer
Important notice and disclaimer This presentation (the "Presentation") has been prepared by EXACT Therapeutics AS (the "Company") exclusively for information purposes. The Presentation is being made only to, and is only directed at, persons to whom such presentation may lawfully be communicated (’re
Slide 3: Today's speakers from management
Today’s speakers from management Anders Wold, Chairman Dr Per Walday, CEO • Joined EXACT December 2021 • Joined EXACT June 2022 • 40 years from start-up to industrial success in Ultrasound • 30+ years developing pharmaceuticals from preclinical to & Med Tech commercialization, including drug-device
Slide 4: Ultrasound – promising and attractive treatment space
Exact Therapeutics market update Ultrasound – promising and attractive treatment space • Ultrasound is gaining momentum as a new, targeted and non-invasive treatment and drug delivery modality, with pharma VCs and other key players entering the stage • 2024: Insightec raised 150 MUSD, round led by F
Slide 5: EXACT introduction
EXACT introduction = ACT,
Slide 6: Leader in non-invasive, ultrasound mediated oncology therapy
Leader in non-invasive, ultrasound mediated oncology therapy We are building a leading, next generation precision medicine Company utilizing the power of ultrasound and microbubbles to enable targeted drug delivery in oncology Spin-out from GE HealthCare – focused oncology development strategy: •
Slide 7: EXACT Therapeutics receives 7 MUSD investment from GE HealthCare
EXACT Therapeutics receives 7 MUSD investment from GE HealthCare GE HealthCare, a global leader in medical technology, forms strategic development agreement with EXACT Therapeutics in a 4-year collaboration within abdominal cancers GE HealthCare participated as cornerstone investor and invest 7
Slide 8: Successful private placement of 13 MUSD / 145 MNOK
Successful private placement of 13 MUSD / 145 MNOK Financing to reach well beyond PoC in pancreatic cancer Private Initial safety Interim Topline placement read-out read-out Results Q4 2024 H1 2025 H1 2026 H1 2027 Total Funding Today $7.4m $2.7m $5.4m Need $15.5m Private placement Warrants for of $1
Slide 9: Strategic focus – Oncology first
EXACT Therapeutics |Strategic focus – Oncology first Pancreatic cancer: Execute on ENACT Phase 2 trial in first line locally 1 advanced pancreatic cancer Explore ACT® in immuno-oncology: Execute on research collaborations 2 with Agenus Inc. and NRC* grant with ICR*, TGen* and NTNU* CNS cancers and b
Slide 10: Rich potential news flow within 1H 2025
Rich potential news flow within 1H 2025 Milestone category Description Oncology (clinical) Phase 1 ACTIVATE study Final study results from ACTIVATE study in patients with liver metastases of colorectal cancer origin Phase 2 ENACT trial FDA Approval of IND for ENACT Phase 2 study in first line locall
Slide 11: Technology
Technology = ACT,
Slide 12: ACT technology defeats biological barriers that hamper drug delivery
The Acoustic Cluster Therapy (ACT®) technology defeats biological barriers that hamper drug delivery • A noninvasive platform to enable targeted, organ-specific drug delivery • ACT treatment is given concomitantly with therapeutics Standard of care therapy Microbubble Microdroplet Ultrasound PS101 i
Slide 13: A simple and non-invasive treatment process
A simple and non-invasive treatment process ACT achieves therapeutic benefit through a 2-step ultrasound process Step 1: Activation with high frequency (HF) Step 2: Enhancement with low frequency (LF) › › › HF ultrasound is applied Resulting in phase shift LF ultrasound is applied Oscillation of ACT
Slide 14: Pancreatic cancer and ENACT Phase 2 study
1 Pancreatic cancer and ENACT Phase 2 study
Slide 15: Pancreatic cancer at a glance
Pancreatic cancer at a glance* Clear unmet medical need • Pancreatic cancer is one of the deadliest cancers • Third most common cancer death • Growing patient population, in particular in younger population groups** • After 5 years, only 12.8% are alive Percentage of Cases by Stage (US) 5-Year Relat
Slide 16: ACT for pancreatic cancer
ACT for pancreatic cancer Strong preclinical data and prominent KOL support Dr. Daniel Von Hoff, Distinguished Prof & national lead expert in pancreatic cancer1) “Pancreatic cancer is notoriously resistant to treatment. The results from the study are some of the most encouraging ones we have seen in
Slide 17: Preclinical Results
Preclinical Results Pancreatic ductal adenocarcinoma 2) Effect of acoustic cluster therapy (ACT®) combined with chemotherapy in a patient-derived xenograft mouse model1) of pancreatic cancer Complete Drug/Combination n Response Rate Nab-paclitaxel + gemcitabine 9 11% Nab-paclitaxel + gemcitabine + A
Slide 18: ENACT Phase 2 study
ENACT Phase 2 study Locally advanced or borderline resectable pancreatic cancer • Phase 2 study to investigate the efficacy and safety of ACT® in combination with Standard of Care treatment in first line locally advanced/regional or borderline resectable pancreatic cancer patients • mOS is 10 months
Slide 19: ENACT Phase 2 study
ENACT Phase 2 study ACT safety and efficacy in first line borderline resectable and locally advanced PDAC1) Staggered dosing for the first three participants Participant 1 Participant 2 Participant 3 Days 14 21 28 - 25 patients with locally advanced pancreatic cancer ~25 participants on ACT + mFOLFI
Slide 20: ACT in immuno-oncology
ACT® in immuno-oncology = ACT,
Slide 21: Expanding Oncology applications into Immuno-oncology
Expanding Oncology applications into Immuno-oncology Very large potential market opportunity • Immuno-oncology (IO) is the greatest revenue generator within oncology with leading drugs such as Merck’s Keytruda® (pembrolizumab) and BMS’ Opdivo® (nivolumab) generating 25 BUSD and 9 BUSD in sales in 20
Slide 22: CNS and Blood-brain barrier
3 CNS and Blood-brain barrier
Slide 23: Targeted drug delivery to the brain
Targeted drug delivery to the brain ACT® can provide targeted, temporary, and safe opening of the blood-brain-barrier • Development of new medicines for brain diseases is severly hampered by the blood-brain barrier (BBB) • Only 2% of small molecule drugs and almost no biologic drugs can pass the BBB
Slide 24: Conclusion and key take-aways
Conclusion and key take-aways
Slide 25: Conclusion and key take-aways
Conclusion and key take-aways 1. Encouraging clinical- and pre-clinical proof of concept for ACT® 2. Focused oncology strategy – Phase 2 ENACT study is first priority 3. Cash and experienced management to execute on strategy 4. #1 medical equipment company as vested partner 5. Rich news flow and nea
Slide 26: ACT - defeating barriers in solid tumours
ACT® - defeating barriers in solid tumours Dr Per Walday Caspar Foghsgaard CEO CBO M: +47 917 93 429 M: +47 454 89 233 E: per.walday@exact-tx.com E: caspar.foghsgaard@exact-tx.com
EXACT Therapeutics — Investor Presentation (December 2024) on 6ix